- Home
- MRUS vs PTCT Comparison
MRUS vs PTCT Comparison
Compare MRUS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- PTCT
- Stock Information
- Founded
- MRUS 2003
- PTCT 1998
- Country
- MRUS Netherlands
- PTCT United States
- Employees
- MRUS N/A
- PTCT N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- MRUS Health Care
- PTCT Health Care
- Exchange
- MRUS Nasdaq
- PTCT Nasdaq
- Market Cap
- MRUS 4.1B
- PTCT 4.1B
- IPO Year
- MRUS 2016
- PTCT 2013
- Fundamental
- Price
- MRUS $66.83
- PTCT $48.43
- Analyst Decision
- MRUS Strong Buy
- PTCT Buy
- Analyst Count
- MRUS 12
- PTCT 14
- Target Price
- MRUS $91.00
- PTCT $68.07
- AVG Volume (30 Days)
- MRUS 661.7K
- PTCT 1.3M
- Earning Date
- MRUS 08-05-2025
- PTCT 08-07-2025
- Dividend Yield
- MRUS N/A
- PTCT N/A
- EPS Growth
- MRUS N/A
- PTCT N/A
- EPS
- MRUS N/A
- PTCT 7.72
- Revenue
- MRUS $56,228,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- MRUS $67.27
- PTCT $120.38
- Revenue Next Year
- MRUS $0.49
- PTCT N/A
- P/E Ratio
- MRUS N/A
- PTCT $6.30
- Revenue Growth
- MRUS 59.77
- PTCT 96.00
- 52 Week Low
- MRUS $33.19
- PTCT $30.41
- 52 Week High
- MRUS $67.59
- PTCT $58.38
- Technical
- Relative Strength Index (RSI)
- MRUS 64.93
- PTCT 49.96
- Support Level
- MRUS $63.21
- PTCT $43.18
- Resistance Level
- MRUS $67.59
- PTCT $49.45
- Average True Range (ATR)
- MRUS 2.22
- PTCT 2.31
- MACD
- MRUS -0.27
- PTCT -0.14
- Stochastic Oscillator
- MRUS 97.33
- PTCT 53.87
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.